In Q2 2024, RTW Investments held 56 positions worth $6.0B. They initiated 6 new positions and exited 28. Their largest holding was MDGL ($536.7M). Portfolio value shrank -1.4% versus the prior quarter.
Frequently asked questions
What stocks did RTW Investments own in Q2 2024?
RTW Investments held 56 biotech stocks in their 13F portfolio in Q2 2024. Their top positions include MDGL, RCKT, AXSM, RNA, ARGX. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was RTW Investments's portfolio worth in Q2 2024?
RTW Investments's tracked biotech portfolio was worth $6.0B across 56 positions, with total assets under management of approximately $10B. Portfolio values are based on 13F filings with the SEC.
What did RTW Investments buy in Q2 2024?
RTW Investments initiated 6 new positions in Q2 2024, including CGEM, TEM, REPL, PCSC, GPCR and 1 more. They also increased 21 existing positions.
What did RTW Investments sell in Q2 2024?
RTW Investments fully exited 28 positions in Q2 2024, including VKTX, RLMD, PMVP, OLK, MLTX and 23 more. They also trimmed 12 existing positions.
Is RTW Investments a biotech fund?
Data-driven biotech fund led by a physician-investor who combines clinical expertise with quantitative analysis. RTW takes concentrated positions across the biotech lifecycle, from crossover privates to public equities, with a focus on therapeutic areas where clinical data can be independently modeled.
Want AI analysis, insider signals, and catalyst overlays for RTW Investments?
View latest RTW Investments portfolio →